PT3219312T - Polímeros de ligação a ião e seus usos - Google Patents

Polímeros de ligação a ião e seus usos

Info

Publication number: PT3219312T
Authority: PT; Portugal
Prior art keywords: binding polymers; hyperkalemia; compositions; ion binding; methods
Prior art date: 2004-03-30

Application number

PT16203827T

Other languages

English (en)

Inventor

Liu Mingjun

Charmot Dominique

James Cope Michael

Klaerner Gerrit

Kwok-Kong Mong Tony

Liu Futian

Chang Hanting

Original Assignee

Relypsa Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-30

Filing date

2005-03-30

Publication date

2019-03-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40774830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3219312(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-03-30 Priority claimed from US10/814,749 external-priority patent/US8192758B2/en

2004-03-30 Priority claimed from US10/814,527 external-priority patent/US7854924B2/en

2004-03-30 Priority claimed from US10/813,872 external-priority patent/US8282960B2/en

2005-03-30 Application filed by Relypsa Inc filed Critical Relypsa Inc

2019-03-01 Publication of PT3219312T publication Critical patent/PT3219312T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F120/04—Acids; Metal salts or ammonium salts thereof
- C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F128/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur
- C08F128/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur by a bond to sulfur

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Inorganic Chemistry (AREA)
Obesity (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Polymers & Plastics (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Dental Preparations (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Processes Of Treating Macromolecular Substances (AREA)
Macromonomer-Based Addition Polymer (AREA)

PT16203827T 2004-03-30 2005-03-30 Polímeros de ligação a ião e seus usos PT3219312T (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US10/814,749 US8192758B2 (en)	2004-03-30	2004-03-30	Ion binding compositions
US10/814,527 US7854924B2 (en)	2004-03-30	2004-03-30	Methods and compositions for treatment of ion imbalances
US10/813,872 US8282960B2 (en)	2004-03-30	2004-03-30	Ion binding compositions
US10/965,274 US7488495B2 (en)	2004-03-30	2004-10-13	Ion binding polymers and uses thereof

Publications (1)

Publication Number	Publication Date
PT3219312T true PT3219312T (pt)	2019-03-01

Family

ID=40774830

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT16203827T PT3219312T (pt)	2004-03-30	2005-03-30	Polímeros de ligação a ião e seus usos
PT101862126T PT2269589E (pt)	2004-03-30	2005-03-30	Polímeros de ligação a ião e seus usos
PT10152337T PT2184059E (pt)	2004-03-30	2005-03-30	Polímeros de ligação a ião e seus usos

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PT101862126T PT2269589E (pt)	2004-03-30	2005-03-30	Polímeros de ligação a ião e seus usos
PT10152337T PT2184059E (pt)	2004-03-30	2005-03-30	Polímeros de ligação a ião e seus usos

Country Status (14)

Country	Link
EP (6)	EP2269589B1 (pt)
JP (4)	JP5600658B2 (pt)
KR (5)	KR20130086262A (pt)
CN (2)	CN102133196B (pt)
AT (2)	ATE460927T1 (pt)
AU (5)	AU2010214729B2 (pt)
CA (2)	CA2806465C (pt)
DE (4)	DE602005019992D1 (pt)
DK (2)	DK2269589T3 (pt)
ES (6)	ES2659386T3 (pt)
GB (2)	GB2456253B (pt)
HK (2)	HK1106133A1 (pt)
PL (3)	PL3219312T3 (pt)
PT (3)	PT3219312T (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104470573B (zh)	2012-07-11	2016-08-24	皇家飞利浦有限公司	患者界面
JP6821571B2 (ja) *	2014-12-23	2021-01-27	アルデリックス，インコーポレイテッド	高カリウム血症を処置するための組成物および方法
CN213938270U (zh) *	2020-04-03	2021-08-10	南京西觉硕信息科技有限公司	一种音频设备
US20240139234A1 (en) *	2021-11-17	2024-05-02	Waterstone Pharmaceuticals (Wuhan) Co., Ltd.	Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
CN117106852B (zh) *	2023-09-04	2024-03-19	济宁市兖州区检验检测中心	一种快速检测农产品农药残留的检测方法及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3031737A1 (de)	1980-08-22	1982-04-01	Bayer Ag, 5090 Leverkusen	Verfahren zur herstellung von perlpolymerisaten einheitlicher teilchengroesse
US4675140A (en)	1984-05-18	1987-06-23	Washington University Technology Associates	Method for coating particles or liquid droplets
CN1010098B (zh) *	1985-05-25	1990-10-24	赫彻斯特股份公司	α-氟代丙烯酸酯聚合物的制备方法
US4837015A (en) *	1987-03-05	1989-06-06	Carolina Medical Products Company, Inc.	Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
FR2634377B1 (fr) *	1988-06-30	1991-09-27	Cortial	Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
GB8829088D0 (en)	1988-12-13	1989-01-25	Smith Kline French Lab	Compounds
US5236701A (en)	1989-07-19	1993-08-17	Lowchol Scientific Inc.	Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de)	1989-09-01	1991-03-07	Bayer Ag	Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en)	1989-11-14	1992-05-12	E. I. Du Pont De Nemours And Company	Process for the preparation of difluoromaleic anhydride
DE69016014T2 (de) *	1990-07-04	1995-08-31	Marcin Krotkiewski	Blutdrucksenkendes Präparat.
DE4139747A1 (de) *	1991-12-03	1993-06-09	Bayer Ag, 5090 Leverkusen, De	Fuellstoffhaltige, optisch aktive perlpolymerisate
WO1994019379A1 (en)	1993-02-17	1994-09-01	British Technology Group Limited	Polymeric compounds
WO1994027619A1 (en) *	1993-05-20	1994-12-08	Geltex Pharmaceuticals, Inc.	Process for adjusting ion concentration in a patient and compositions therefor
US5607669A (en)	1994-06-10	1997-03-04	Geltex Pharmaceuticals, Inc.	Amine polymer sequestrant and method of cholesterol depletion
US5496545A (en)	1993-08-11	1996-03-05	Geltex Pharmaceuticals, Inc.	Phosphate-binding polymers for oral administration
US5667775A (en)	1993-08-11	1997-09-16	Geltex Pharmaceuticals, Inc.	Phosphate-binding polymers for oral administration
WO1995014531A1 (en) *	1993-11-25	1995-06-01	Salternate B.V.	Particles for binding monovalent cations, use of such particles as well as methods for scavenging and removing sodium and/or potassium ions
WO1996021454A1 (en)	1995-01-12	1996-07-18	Geltex Pharmaceuticals, Inc.	Phosphate-binding polymers for oral administration
GB9503061D0 (en)	1995-02-16	1995-04-05	British Tech Group	Polymeric compounds
EP0793960B1 (en)	1996-03-05	2001-08-01	Mitsubishi Chemical Corporation	Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia
US6491903B1 (en) *	1996-06-27	2002-12-10	Washington University	Particles comprising amphiphilic copolymers
WO1998003185A1 (fr) *	1996-07-19	1998-01-29	Nikken Chemicals Co., Ltd.	Remedes contre l'hyperphosphatemie
BR9712660A (pt)	1996-10-23	2000-10-24	Dow Chemical Co	Polìmeros solúveis em água para redução de fosfato dietético ou absorção de oxalato
AU2446497A (en)	1997-03-25	1998-10-20	Geltex Pharmaceuticals, Inc.	Phosphate-binding polymers combined with a calcium supplement for oral administration
US6423754B1 (en)	1997-06-18	2002-07-23	Geltex Pharmaceuticals, Inc.	Method for treating hypercholesterolemia with polyallylamine polymers
US5985938A (en)	1997-11-05	1999-11-16	Geltex Pharmaceuticals, Inc.	Method for reducing oxalate
US6726905B1 (en)	1997-11-05	2004-04-27	Genzyme Corporation	Poly (diallylamines)-based phosphate binders
US6475510B1 (en)	1997-12-19	2002-11-05	Smithkline Beecham Corporation	Process for manufacturing bite-dispersion tablets
US6294163B1 (en)	1998-10-02	2001-09-25	Geltex Pharmaceuticals, Inc.	Polymers containing guanidinium groups as bile acid sequestrants
AU1998200A (en) *	1999-01-07	2000-07-24	Elan Corporation, Plc	Multiparticulate oral dosage forms
CA2377739A1 (en)	1999-07-02	2001-01-11	Symyx Technologies, Inc.	Polymer brushes for immobilizing molecules to a surface or substrate, where the polymers have water-soluble or water-dispersible segments and probes bonded thereto
KR20020026366A (ko)	1999-08-09	2002-04-09	한스 루돌프 하우스, 헨리에데 부르너	단백질의 생산
US6733780B1 (en)	1999-10-19	2004-05-11	Genzyme Corporation	Direct compression polymer tablet core
US20020054903A1 (en) *	1999-10-19	2002-05-09	Joseph Tyler	Direct compression polymer tablet core
ATE286386T1 (de)	1999-10-19	2005-01-15	Genzyme Corp	Direktkomprimierter tablettenkern auf polymerbasis
DE60132256T2 (de)	2000-11-20	2008-12-24	Sorbent Therapeutics, Inc., Vernon Hills	Wasserabsorbierende polymere und deren verwendung
KR20040018357A (ko)	2001-04-18	2004-03-03	젠자임 코포레이션	저염 형태의 폴리알릴아민
US20030099711A1 (en) *	2001-08-29	2003-05-29	David Meadows	Sustained release preparations
GB2430624B (en) *	2004-03-30	2009-08-05	Ilypsa Inc	Ion binding compositions

2005
- 2005-03-30 EP EP10186212.6A patent/EP2269589B1/en active Active
- 2005-03-30 CN CN201110065007.8A patent/CN102133196B/zh not_active Expired - Fee Related
- 2005-03-30 EP EP16203827.7A patent/EP3219312B1/en active Active
- 2005-03-30 DE DE602005019992T patent/DE602005019992D1/de active Active
- 2005-03-30 ES ES09176701.2T patent/ES2659386T3/es active Active
- 2005-03-30 ES ES10152337T patent/ES2388052T3/es active Active
- 2005-03-30 EP EP10152337A patent/EP2184059B1/en active Active
- 2005-03-30 AT AT05732849T patent/ATE460927T1/de active
- 2005-03-30 KR KR1020137017864A patent/KR20130086262A/ko not_active Application Discontinuation
- 2005-03-30 KR KR1020127013106A patent/KR101269766B1/ko active IP Right Grant
- 2005-03-30 PL PL16203827T patent/PL3219312T3/pl unknown
- 2005-03-30 PT PT16203827T patent/PT3219312T/pt unknown
- 2005-03-30 DK DK10186212.6T patent/DK2269589T3/da active
- 2005-03-30 ES ES05732849T patent/ES2339571T3/es active Active
- 2005-03-30 GB GB0906966A patent/GB2456253B/en active Active
- 2005-03-30 PL PL10186212T patent/PL2269589T3/pl unknown
- 2005-03-30 KR KR1020127026913A patent/KR101362509B1/ko active IP Right Grant
- 2005-03-30 PL PL10152337T patent/PL2184059T3/pl unknown
- 2005-03-30 KR KR1020117029211A patent/KR101223335B1/ko active IP Right Grant
- 2005-03-30 PT PT101862126T patent/PT2269589E/pt unknown
- 2005-03-30 DK DK16203827.7T patent/DK3219312T3/en active
- 2005-03-30 ES ES05731099T patent/ES2338667T3/es active Active
- 2005-03-30 ES ES10186212.6T patent/ES2453048T3/es active Active
- 2005-03-30 GB GB0907161A patent/GB2456256B/en not_active Expired - Fee Related
- 2005-03-30 EP EP09176701.2A patent/EP2158902B1/en not_active Not-in-force
- 2005-03-30 DE DE112005000725.1T patent/DE112005000725B4/de not_active Expired - Fee Related
- 2005-03-30 DE DE602005018619T patent/DE602005018619D1/de active Active
- 2005-03-30 PT PT10152337T patent/PT2184059E/pt unknown
- 2005-03-30 ES ES16203827T patent/ES2720612T3/es active Active
- 2005-03-30 AT AT05731099T patent/ATE453383T1/de not_active IP Right Cessation
- 2005-03-30 EP EP10186221A patent/EP2269590A3/en not_active Ceased
- 2005-03-30 DE DE112005000708.1T patent/DE112005000708B4/de not_active Expired - Fee Related
- 2005-03-30 EP EP19153950.1A patent/EP3574896A1/en not_active Withdrawn
- 2005-03-30 CA CA2806465A patent/CA2806465C/en active Active
- 2005-03-30 CA CA2829943A patent/CA2829943C/en not_active Expired - Fee Related
- 2005-03-30 KR KR1020137034227A patent/KR101399238B1/ko active IP Right Grant
- 2005-03-30 CN CN201310137951.9A patent/CN103251571B/zh active Active
2007
- 2007-10-22 HK HK07111381.7A patent/HK1106133A1/xx not_active IP Right Cessation
2008
- 2008-01-07 HK HK08100150.8A patent/HK1109338A1/xx unknown
2010
- 2010-08-30 AU AU2010214729A patent/AU2010214729B2/en active Active
- 2010-08-30 AU AU2010214732A patent/AU2010214732B2/en not_active Ceased
2011
- 2011-11-08 JP JP2011244902A patent/JP5600658B2/ja active Active
- 2011-11-10 JP JP2011246755A patent/JP5431439B2/ja not_active Expired - Fee Related
2012
- 2012-10-31 JP JP2012240298A patent/JP5671511B2/ja active Active
- 2012-11-14 AU AU2012254879A patent/AU2012254879B2/en active Active
2013
- 2013-11-29 JP JP2013246976A patent/JP2014040484A/ja not_active Withdrawn
2016
- 2016-08-19 AU AU2016216697A patent/AU2016216697C1/en active Active
2018
- 2018-07-17 AU AU2018206706A patent/AU2018206706B2/en active Active

Also Published As

Publication number	Publication date
ES2339571T3 (es)	2010-05-21
GB0907161D0 (en)	2009-06-10
ES2453048T3 (es)	2014-04-03
KR20130086262A (ko)	2013-07-31
EP2184059B1 (en)	2012-06-27
JP2012031210A (ja)	2012-02-16
JP5600658B2 (ja)	2014-10-01
JP5671511B2 (ja)	2015-02-18
ATE460927T1 (de)	2010-04-15
GB2456253A (en)	2009-07-15
HK1109338A1 (en)	2008-06-06
CA2829943C (en)	2017-03-14
JP2013056909A (ja)	2013-03-28
KR101223335B1 (ko)	2013-01-17
JP5431439B2 (ja)	2014-03-05
EP2269590A2 (en)	2011-01-05
AU2018206706B2 (en)	2020-08-06
AU2010214729B2 (en)	2012-08-16
JP2014040484A (ja)	2014-03-06
AU2010214729A1 (en)	2010-09-23
HK1106133A1 (en)	2008-03-07
AU2010214732A1 (en)	2010-09-23
ATE453383T1 (de)	2010-01-15
EP2269589B1 (en)	2013-12-25
KR101399238B1 (ko)	2014-05-27
KR101362509B1 (ko)	2014-02-13
CN103251571B (zh)	2016-08-17
CN103251571A (zh)	2013-08-21
KR20110138300A (ko)	2011-12-26
DE112005000708T5 (de)	2007-02-15
PL3219312T3 (pl)	2019-07-31
EP3219312B1 (en)	2019-01-30
DE112005000725B4 (de)	2017-12-21
DK2269589T3 (da)	2014-03-31
KR101269766B1 (ko)	2013-05-30
DE112005000725T5 (de)	2007-05-03
JP2012025783A (ja)	2012-02-09
GB2456253B (en)	2009-08-26
ES2659386T3 (es)	2018-03-15
DE602005019992D1 (de)	2010-04-29
EP2269590A3 (en)	2011-10-05
AU2016216697B2 (en)	2018-04-19
EP2269589A2 (en)	2011-01-05
AU2010214732B2 (en)	2012-07-12
KR20120130255A (ko)	2012-11-29
EP2158902A1 (en)	2010-03-03
ES2338667T3 (es)	2010-05-11
EP3574896A1 (en)	2019-12-04
PL2269589T3 (pl)	2014-05-30
DE602005018619D1 (de)	2010-02-11
GB2456256B (en)	2009-08-26
EP2158902B1 (en)	2017-12-06
DE112005000708B4 (de)	2017-12-21
PT2269589E (pt)	2014-02-26
EP2184059A3 (en)	2010-05-19
CA2829943A1 (en)	2005-10-20
CN102133196B (zh)	2015-01-21
KR20140003661A (ko)	2014-01-09
AU2018206706A1 (en)	2018-08-02
CA2806465A1 (en)	2005-10-20
PL2184059T3 (pl)	2013-01-31
AU2016216697A1 (en)	2016-09-08
AU2012254879A1 (en)	2012-12-13
ES2720612T3 (es)	2019-07-23
GB0906966D0 (en)	2009-06-03
EP2184059A2 (en)	2010-05-12
EP2269589A3 (en)	2011-10-05
ES2388052T3 (es)	2012-10-08
KR20120060920A (ko)	2012-06-12
AU2012254879B2 (en)	2016-05-19
PT2184059E (pt)	2012-07-06
CN102133196A (zh)	2011-07-27
GB2456256A (en)	2009-07-15
AU2016216697C1 (en)	2019-03-21
EP3219312A1 (en)	2017-09-20
CA2806465C (en)	2016-05-24
DK3219312T3 (en)	2019-04-01

Publication	Publication Date	Title
GB2430367B (en)	2009-08-05	Ion binding polymers and uses thereof
WO2005092039A3 (en)	2005-12-08	Crosslinked amine polymers
GB2446076A (en)	2008-07-30	Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
EP1831266A4 (en)	2007-12-05	RETICULATED AMINE POLYMERS
GB2446077A (en)	2008-07-30	Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
WO2006124748A3 (en)	2007-03-01	Multicyclic compounds and methods of their use
WO2007136969A3 (en)	2008-02-21	Bioabsorbable magnesium-reinforced polymer stents
WO2007057714A3 (en)	2007-10-11	Pharmaceutical compositions comprising methotrexate
WO2007038801A3 (en)	2007-11-08	Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
WO2005085188A3 (en)	2006-06-15	Compounds and methods for anti-tumor therapy
WO2009114461A3 (en)	2009-11-12	Angiotensin (1-7) dosage forms and uses thereof
HK1109338A1 (en)	2008-06-06	Ion binding polymers and uses thereof
WO2009023544A3 (en)	2009-03-19	Dosage unit anion-exchange polymer pharmaceutical compositions
WO2008112325A3 (en)	2009-12-23	Treatment of autoimmune disorders
WO2009078978A3 (en)	2009-12-03	Compositions containing polyglycidol-based polymers and uses thereof
WO2006078336A3 (en)	2006-11-30	Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2004018010A3 (en)	2004-07-08	Methods of drug delivery using sulphated chitinous polymers
WO2007123686A3 (en)	2008-07-03	Dpp inhibitors and uses thereof
WO2008070778A3 (en)	2008-10-09	Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
WO2007116278A3 (en)	2007-12-21	Antiangiogenic peptide and therapeutic uses thereof
MY146274A (en)	2012-07-31	Pharmaceutical compositions and methods relating to fucans